$Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

Healthcare ratings roundup - upgrades/downgrades

Bayer AG (OTCPK:BAYRY) upgraded to Buy from Neutral by Citigroup.

Allscripts (NASDAQ:MDRX) upgraded to Outperform from Market Perform by Leerink Swann. Price target raised to $17 (32% upside) from $16.

Healthways (NASDAQ:HWAY) upgraded to Equal Weight from Underweight by Barclays. Price target raised to $27 (10% upside) from $12.

Cardiovascular Systems (NASDAQ:CSII) upgraded to Outperform from Market Perform by Leerink Swann. Price target is $30 (26% upside).

Allergan plc (NYSE:AGN) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $318 (35% upside) from $248.

Healthways (HWay) downgraded to Sell from Neutral by UBS. Price target raised to $22.50 (8% downside risk) from $19.

ResMed (NYSE:RMD) downgraded to Underperform from Hold by Jefferies. Price target lowered to $58 (15% downside risk) from $60.

Relypsa (NASDAQ:RLYP) downgraded to Hold from Buy by Stifel Nicolaus. Price target is $32 (0% upside).

Portola Pharmaceuticals (NASDAQ:PTLA) downgraded to Neutral from Buy by Citigroup. Price target lowered to $24 (21% upside) from $40.

Juniper Pharmaceuticals (NASDAQ:JNP) downgraded to Neutral from Buy by H.C. Wainwright. Price target is $6.75 (17% upside).